Lytenava (bevacizumab gamma), is the first licensed version of Avastin for wet age-related macular degeneration. The treatment was approved by the National Institute for Health and Care Excellence (NICE) for use in the NHS last year.
Join our monthly webinar as professor Andrew Lotery will break down what this new treatment means for you. He’ll also discuss how Lytenava compares to existing treatments, such as Eylea and Lucentis, its potential benefits, and what this approval means for NHS patients.
This webinar will be taking place at 7pm on Tuesday 18 February.
To register please use the link below
us02web.zoom.us/webinar/reg...
Our webinars are also posted on our website a few days after the live event. Please refer to the link below
macularsociety.org/support/...
Best wishes,
Carol
Macular Society Helpline
Levodopa being trialled for AMD
laser treatment for wet amd?
Wet AMD or Central Serous Retinopathy?
"Virtual" assessments for AMD
WET AMD
